Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

Sponsor
University of Luebeck
Study ID
NCT07389941
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Atrial Fibrillation (AF)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide (SEMA) — DRUG
    Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)

Study Details

To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.

Key Dates

Start date
Oct 31, 2026
Status verified
Feb 2026
Primary completion
Apr 30, 2029
Completion
Apr 30, 2029

Study Design

Enrollment
240 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Catheter ablation for atrial fibrillation plus semaglutide
    Catheter ablation for atrial fibrillation plus semaglutide (up to 2.4 mg weekly)
  • No Intervention: Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy
    Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy (standard therapy)

Primary Outcome Measure

Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period) [ Time Frame: 12 months ]

Related Studies